Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to two new employees to purchase an aggregate of 60,000 shares of the Company's common stock, effective as of December 2, 2024. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
舊金山，2024年12月3日（環球新聞）——Olema製藥公司（「Olema」或「Olema腫瘤學」，納斯達克：OLMA）是一家臨床階段的生物製藥公司，專注於針對乳腺癌及其他疾病的靶向治療的發現、開發和商業化。今日，公司宣佈已向兩名新員工授予購買公司普通股合計60,000股的期權，生效日期爲2024年12月2日。這些獎勵經過Olema董事會薪酬委員會的批准，並根據公司的2022年誘導計劃提供，作爲新員工入職Olema的誘導材料，符合納斯達克上市規則5635(c)(4)。
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $10.21 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on December 2, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
這些期權在四年內歸屬，第一年歸屬日期的25%將在該名員工的歸屬週年日歸屬，其餘的將在接下來的三年中按36個月均等分期歸屬，前提是員工在這些歸屬日期時繼續在Olema工作。這些期權的有效期爲10年，行使價格爲每股10.21美元，等於2024年12月2日公司普通股在納斯達克上最後報告的交易價格。這些期權受Olema製藥公司2022年誘導計劃的條款約束。
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema根據納斯達克上市規則5635(c)(4)提供此信息。
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at .
關於Olema腫瘤學
Olema腫瘤學是一家臨床階段的生物製藥公司，致力於改變護理標準並改善生活在癌症中的女性的治療結果。Olema通過深刻理解內分泌驅動的癌症、核受體及獲得性抵抗機制，推動一系列新療法的發展。我們的主要產品候選藥物palazestrant (OP-1250)是一種專有的口服可用完全雌激素受體拮抗劑（CERAN）和選擇性ER降解劑（SERD），目前正在進行一項名爲OPERA-01的三期臨床試驗。此外，Olema還在開發一種有效的KAT6抑制劑（OP-3136）。Olema總部位於舊金山，在馬薩諸塞州劍橋市設有業務。想要了解更多信息，請訪問我們的網站。
Media and Investor Relations Contact
媒體和投資者關係聯繫人
Courtney O'Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
考特妮·奧科內克
企業通信副總裁
Olema腫瘤學
media@olema.com
